Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lyon – page 12

1 204 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
1 204
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 204 trials in Lyon

Open in trial search

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Ellipses Pharma Limited

Chronic obstructive pulmonary disease

Recruiting

Long-term Safety Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease and History of Exacerbations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Transitional cell carcinoma metastatic

Recruiting

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Recruiting

A Study of Brivekimig Compared to Placebo in Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Renal transplant

Recruiting

A Study of Felzartamab for Kidney Transplant Patients with Late Isolated Microvascular Inflammation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited

Hepatocellular carcinoma+2

Recruiting

Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RP2
  • Sponsor:Replimune Group Inc.

Ovarian cancer

Recruiting

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer metastatic

Recruiting

A Study of Evorpacept Combined with Trastuzumab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Alx Oncology Holdings Inc.

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.